You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of Zika viral pseudoinfectious virus as Zika vaccine candidate

    SBC: Tengen Biomedical Co            Topic: NIAID

    Executive Summary of Predicate SBIR/STTR Phase I Grant and Team TenGen Biomedical Co. and Howard University received an STTR Phase I grant (5R41AI129119-02) from the National Institute of Allergy and Infectious Diseases (NIAID) in 2017. The overall objective of our predicate STTR Phase I grant is to develop a safe, effective, and affordable Zika vaccine based on the novel concept of the third gene ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Immunotherapeutics to prevent HCV reinfection

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Up to 170 million people worldwide are chronically infected with HCV Hepatitis C virus (HCV) putting the infected individuals at significant risk for cirrhosis, liver failure and liver cancer. End- stage liver diseasecaused by HCV is the leading indication of liver transplantation (LT) in the United States. However, reinfection with HCV occurs universally and ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. RNA Detection as an Improved Diagnostic Assay for Human Leptospirosis

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    DESCRIPTION provided by applicant Leptospirosis a zoonotic disease is an important public health problem worldwide It is caused by spirochete bacteria belonging to nine species and more than serovars of the genus Leptospira In the US there is increasing awareness of the importance of leptospirosis as the cause of disease among inner city populations military personnel and individuals ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. A Multivalent Lyme Disease Vaccine Targeting Tick-Host-Pathogen Interactions

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    DESCRIPTION provided by applicant This proposal seeks to develop a novel vaccine against Lyme disease by targeting Ixodes scapularis proteins critical for Borrelia burgdorferi transmission from the tick to mammalian host Earlier work has identified four tick proteins Salp TRE tHRF and TSLPI that facilitate different steps of spirochete transmission and immunity against these protein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis

    SBC: Integrated Biotherapeutics, Inc.            Topic: r

    Project Summary The Gram positive bacterium Bacillus anthracis is a very strong candidate for potential bioweaponizationand believed to have actually been weaponized by the former Soviet UnionAnthrax spores are readily found in nature or produced in the laboratoryare resistant to harsh conditionsand can survive for a long time in the environmentThe microscopic spores could be formulated in powder ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Targeting STT3A and STT3B to Block Flavivirus Replication

    SBC: New England Discovery Partners, LLC            Topic: NIAID

    AbstractMosquito borne flaviviruses cause disease worldwidewith members such as dengue virusDENVZika virusZIKVand west nile virusWNVinfecting more thanmillion individuals annuallyThe availability of small molecule antivirals that reduce flavivirus infection therefore could have an immediate and substantial impact on public health programs that seek to improve outcomes for populations infected with ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Humanized Monoclonal Antibodies to Treat Acinetobacter Infections

    SBC: BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): In the last decade, Acinetobacter baumannii has emerged as one of the most highly antibiotic-resistant pathogens in the United States (US) and throughout the world. These infections are increasingly prevalent and highlylethal, killing 50-60% of those infected. Worse, strains of A. baumannii that no known antibiotic will kill have now emerged, and will continue ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Validation of a Diagnostic Test for Borrelia miyamotoi

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    ABSTRACT Borrelia miyamotoi is a tick transmitted spirochete recently shown to cause infection and disease in the United StatesEurope and AsiaA member of the relapsing fever group of Borreliathis pathogen has been proven to cause most commonly a nonspecificflu like illness with feverfatiguemyalgiaand headacheDisease can be particularly severe and involve the central nervous system in immunocomprom ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. In Vivo Editing for Hemophilia Gene Therapy

    SBC: GENVEC, INC.            Topic: 100

    Project Summary The exceptional promise of gene therapy for hemophilia has been shown in recent studies that result in long term correction of factor IX deficiency via hepatic transduction with an adeno associated vector AAV In spite of this watershed event in the history of the gene therapy field there presently exist barriers to the fullest implementation of hemophilia gene therapy The li ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government